ALX Oncology Holdings Inc. Profile Avatar - Palmy Investing

ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatm…

Biotechnology
US, South San Francisco [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

ALX Oncology Holdings Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

ALX Oncology Holdings Inc. can't present revenue by segment

End of ALXO's Analysis
CIK: 1810182 CUSIP: 00166B105 ISIN: US00166B1052 LEI: - UEI: -
Secondary Listings
ALXO has no secondary listings inside our databases.